(Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophrenia, and vaccines for flu, rabies and polio.
It said products launched since 2009 will account for nearly half of its pharmaceutical sales by 2017. It also said it plans to continue developing its pipeline of new development-stage drugs in Japan and China, where it also has drugs in later stages of development.
The diversified healthcare company issued the statement ahead of an all-day meeting with hundreds of analysts and fund managers at its headquarters in New Brunswick, New Jersey, to discuss trends for its pharmaceuticals business.
By 2017, it expects to file two more drug applications in Japan and nine in China, the company said.
J&J shares were trading at $87.34 in premarket activity, down from a close of $88.46 on Wednesday.
(Reporting by Caroline Humer and Ransdell Pierson; Editing by Gerald E. McCormick and John Wallace)
Source: http://news.yahoo.com/johnson-johnson-plans-more-10-drugs-filed-2017-120537335.html
Michelle Obama Speech Michael Clarke Duncan Nazanin Boniadi Deval Patrick Dedication 4 labor day college football scores
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন